Neonatal Toxoplasma gondii IgM FEIA
A fluorometric enzyme immunoassay designed for the quantitative determination of IgM-class antibodies to Toxoplasma gondii in dried blood spot samples — enabling effective screening for congenital ....
Overview
Labsystems Diagnostics Neonatal Toxoplasma gondii IgM FEIA is the first neonatal screening test in the world developed for the detection of congenital toxoplasmosis (CT). The assay uses a sensitive fluorometric enzyme immunoassay (FEIA) technique to measure IgM-class antibodies to Toxoplasma gondii from dried blood spots collected on filter paper — ensuring efficient, reliable, and high-throughput screening of newborns. A 5-year study conducted in Brazil screened over 285,000 neonates using this assay and established a prevalence rate of 1:18,867, validating the test’s clinical performance and reliability in large-scale screening programs.
Features
- Quantitative fluorometric enzyme immunoassay (FEIA)
- Detects IgM-class antibodies to Toxoplasma gondii from dried blood spot samples
- Designed specifically for neonatal screening programs
- High sensitivity and reproducibility
- Clinically validated through extensive field studies
- Compatible with Labsystems Diagnostics Neonatal platform
Technical Specifications
- Format : 5 strip plates (12 × 8) - 480 wells
- Sample Type : Dried blood spots on filter paper
- Assay Principle : Fluorometric enzyme immunoassay
- Catalogue Number : 6199802
Benefits
- First neonatal toxoplasma screening test in the world
- Quantitative and accurate results for confident diagnosis
- Clinically proven performance across large population studies
- High-sensitivity capture test ensuring early and reliable detection